CY1119199T1 - Αναστολεις cdc7 - Google Patents
Αναστολεις cdc7Info
- Publication number
- CY1119199T1 CY1119199T1 CY20171100861T CY171100861T CY1119199T1 CY 1119199 T1 CY1119199 T1 CY 1119199T1 CY 20171100861 T CY20171100861 T CY 20171100861T CY 171100861 T CY171100861 T CY 171100861T CY 1119199 T1 CY1119199 T1 CY 1119199T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cdc7
- suspensions
- isoindolinone
- cancer
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
Η παρούσα εφεύρεση παρέχει ενώσεις ισοϊνδολινόνης ή φαρμακευτικώς αποδεκτό άλας αυτών που αναστέλλουν CDC7 και συνεπώς μπορεί να είναι χρήσιμες στην θεραπεία καρκίνου.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782798P | 2013-03-14 | 2013-03-14 | |
| US201361789108P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/021466 WO2014143601A1 (en) | 2013-03-14 | 2014-03-07 | CDC7 Inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119199T1 true CY1119199T1 (el) | 2018-02-14 |
Family
ID=50382704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100861T CY1119199T1 (el) | 2013-03-14 | 2017-08-10 | Αναστολεις cdc7 |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US9156824B2 (el) |
| EP (1) | EP2970221B1 (el) |
| JP (1) | JP6064079B2 (el) |
| KR (1) | KR101718645B1 (el) |
| CN (1) | CN105008351B (el) |
| AP (1) | AP2015008734A0 (el) |
| AU (1) | AU2014228374B2 (el) |
| BR (1) | BR112015020466B1 (el) |
| CA (1) | CA2900773C (el) |
| CL (1) | CL2015002530A1 (el) |
| CR (1) | CR20150416A (el) |
| CY (1) | CY1119199T1 (el) |
| DK (1) | DK2970221T3 (el) |
| EA (1) | EA027012B1 (el) |
| ES (1) | ES2639793T3 (el) |
| GT (1) | GT201500263A (el) |
| HK (1) | HK1212696A1 (el) |
| HR (1) | HRP20171151T1 (el) |
| HU (1) | HUE033482T2 (el) |
| IL (1) | IL240962B (el) |
| JO (1) | JO3383B1 (el) |
| LT (1) | LT2970221T (el) |
| ME (1) | ME02805B (el) |
| MX (1) | MX363438B (el) |
| MY (1) | MY188145A (el) |
| NZ (1) | NZ710392A (el) |
| PE (1) | PE20151654A1 (el) |
| PH (1) | PH12015502091A1 (el) |
| PL (1) | PL2970221T3 (el) |
| PT (1) | PT2970221T (el) |
| RS (1) | RS56122B1 (el) |
| SG (1) | SG11201507541PA (el) |
| SI (1) | SI2970221T1 (el) |
| TN (1) | TN2015000349A1 (el) |
| TW (1) | TWI622396B (el) |
| UA (1) | UA116125C2 (el) |
| WO (1) | WO2014143601A1 (el) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2615743T3 (es) * | 2012-10-15 | 2017-06-08 | Pfizer Ireland Pharmaceuticals | Procedimiento de preparación de voriconazol y análogos de los mismos |
| WO2014110574A1 (en) | 2013-01-14 | 2014-07-17 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| SG10201705662WA (en) | 2013-01-15 | 2017-08-30 | Incyte Corp | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
| TWI627174B (zh) | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調控劑 |
| NZ710034A (en) | 2013-03-14 | 2020-06-26 | Boehringer Ingelheim Int | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| WO2014152537A1 (en) | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | P2x7 modulators |
| JO3773B1 (ar) | 2013-03-14 | 2021-01-31 | Janssen Pharmaceutica Nv | معدلات p2x7 |
| EP2970271B1 (en) | 2013-03-14 | 2017-11-08 | Janssen Pharmaceutica NV | P2x7 modulators |
| PE20160532A1 (es) | 2013-08-23 | 2016-05-21 | Incyte Corp | Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| ES2714048T3 (es) | 2014-09-12 | 2019-05-24 | Janssen Pharmaceutica Nv | Moduladores de P2X7 |
| KR102510588B1 (ko) | 2014-09-12 | 2023-03-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 카텝신 c의 스피로사이클릭 억제제 |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
| EP3515903B1 (en) * | 2016-09-22 | 2020-10-21 | Cancer Research Technology Limited | Preparation and uses of pyrimidinone derivatives |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| CN108383771A (zh) * | 2018-01-08 | 2018-08-10 | 华东师范大学 | 手性3,3-二取代异吲哚啉-1-酮衍生物及其合成方法和应用 |
| GB201807147D0 (en) | 2018-05-01 | 2018-06-13 | Oncologica Uk Ltd | Therapeutic combination |
| NL2021185B1 (en) | 2018-06-26 | 2020-01-06 | Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis | Combination Therapy and Use Thereof for Treating Cancer |
| EP3856178A1 (en) | 2018-09-28 | 2021-08-04 | Janssen Pharmaceutica NV | Monoacylglycerol lipase modulators |
| EP3856179A1 (en) | 2018-09-28 | 2021-08-04 | Janssen Pharmaceutica N.V. | Monoacylglycerol lipase modulators |
| US20220220125A1 (en) * | 2019-04-16 | 2022-07-14 | Janssen Pharmaceutica Nv | Fused isoindolin-1-one derivatives useful as grk2 inhibitors |
| US11839663B2 (en) | 2019-09-30 | 2023-12-12 | Janssen Pharmaceutica Nv | Radiolabelled MGL pet ligands |
| JP2023518511A (ja) | 2020-03-26 | 2023-05-01 | ヤンセン ファーマシューティカ エヌ．ベー． | モノアシルグリセロールリパーゼ調節因子 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0400970D0 (sv) * | 2004-04-14 | 2004-04-14 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| US7576082B2 (en) * | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| WO2008060789A2 (en) * | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
| BRPI0811065A2 (pt) * | 2007-06-08 | 2014-12-02 | Abbott Lab | Indazóis 5-heteroaril substituídos como inibidores de quinase |
| US8648069B2 (en) * | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
-
2014
- 2014-03-04 JO JOP/2014/0067A patent/JO3383B1/ar active
- 2014-03-05 TW TW103107546A patent/TWI622396B/zh active
- 2014-03-07 JP JP2016500764A patent/JP6064079B2/ja active Active
- 2014-03-07 CN CN201480011202.4A patent/CN105008351B/zh active Active
- 2014-03-07 DK DK14712966.2T patent/DK2970221T3/en active
- 2014-03-07 CA CA2900773A patent/CA2900773C/en active Active
- 2014-03-07 ME MEP-2017-173A patent/ME02805B/me unknown
- 2014-03-07 EA EA201591509A patent/EA027012B1/ru not_active IP Right Cessation
- 2014-03-07 MX MX2015012583A patent/MX363438B/es unknown
- 2014-03-07 KR KR1020157024644A patent/KR101718645B1/ko not_active Application Discontinuation
- 2014-03-07 LT LTEP14712966.2T patent/LT2970221T/lt unknown
- 2014-03-07 NZ NZ710392A patent/NZ710392A/en unknown
- 2014-03-07 SI SI201430280T patent/SI2970221T1/sl unknown
- 2014-03-07 EP EP14712966.2A patent/EP2970221B1/en active Active
- 2014-03-07 AP AP2015008734A patent/AP2015008734A0/xx unknown
- 2014-03-07 AU AU2014228374A patent/AU2014228374B2/en active Active
- 2014-03-07 SG SG11201507541PA patent/SG11201507541PA/en unknown
- 2014-03-07 PE PE2015001925A patent/PE20151654A1/es active IP Right Grant
- 2014-03-07 RS RS20170791A patent/RS56122B1/sr unknown
- 2014-03-07 MY MYPI2015703062A patent/MY188145A/en unknown
- 2014-03-07 PT PT147129662T patent/PT2970221T/pt unknown
- 2014-03-07 HU HUE14712966A patent/HUE033482T2/en unknown
- 2014-03-07 WO PCT/US2014/021466 patent/WO2014143601A1/en active Application Filing
- 2014-03-07 PL PL14712966T patent/PL2970221T3/pl unknown
- 2014-03-07 ES ES14712966.2T patent/ES2639793T3/es active Active
- 2014-03-07 BR BR112015020466-0A patent/BR112015020466B1/pt active IP Right Grant
- 2014-03-07 UA UAA201508675A patent/UA116125C2/uk unknown
- 2014-03-07 US US14/200,141 patent/US9156824B2/en active Active
-
2015
- 2015-08-12 TN TN2015000349A patent/TN2015000349A1/en unknown
- 2015-08-14 CR CR20150416A patent/CR20150416A/es unknown
- 2015-08-31 IL IL240962A patent/IL240962B/en active IP Right Grant
- 2015-09-09 GT GT201500263A patent/GT201500263A/es unknown
- 2015-09-09 CL CL2015002530A patent/CL2015002530A1/es unknown
- 2015-09-14 PH PH12015502091A patent/PH12015502091A1/en unknown
-
2016
- 2016-01-21 HK HK16100636.2A patent/HK1212696A1/zh unknown
-
2017
- 2017-07-27 HR HRP20171151TT patent/HRP20171151T1/hr unknown
- 2017-08-10 CY CY20171100861T patent/CY1119199T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119199T1 (el) | Αναστολεις cdc7 | |
| CY1124959T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
| CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
| CY1120556T1 (el) | Δικυκλικα ετεροκυκλα ως αναστολεις fgfr | |
| CY1123633T1 (el) | Ετεροκυκλικες ενωσεις και οι χρησεις αυτων | |
| HK1256283A1 (zh) | 治療癌症有用的二氫咪唑並吡嗪酮衍生物 | |
| CY1119709T1 (el) | Αντιμυκητιασικοι παραγοντες και χρησεις αυτων | |
| DK3469425T3 (da) | Strålingskilde | |
| KR20180084772A (ko) | 암 치료를 위한 조합 치료법 | |
| CY1123592T1 (el) | Αναστολεας κινασης aurora a | |
| KR102377742B1 (ko) | 암치료약 | |
| IL249220A0 (en) | Use of Aribolin in the treatment of cancer | |
| DK3606926T3 (da) | Heteroaromatiske forbindelser anvendelige i terapi | |
| DK3383872T3 (da) | 1,3,4-thiadiazolforbindelser og anvendelse deraf i cancerbehandling | |
| DK3576740T3 (da) | Cancerbehandling | |
| DK3407909T3 (da) | Cancerbehandling | |
| IL253933A0 (en) | History of pyrimidine use in the treatment of cancer | |
| EP3440052C0 (en) | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | |
| MA43648A (fr) | Conjugués de nanoparticules | |
| DK3383871T3 (da) | 1,3,4-thiadiazolforbindelser og anvendelse deraf i behandling af cancer | |
| DK3380468T3 (da) | Bis-pyridazinforbindelser og anvendelse heraf i behandling af cancer | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| DK3630112T3 (da) | Kombination af regorafenib og nivolumab til behandling af cancer | |
| TWI799438B (zh) | 半星芒體衍生物及此等之抗體藥物複合體 | |
| CY1125266T1 (el) | To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων |